BVS vs MDT
BVS: Bioventus is an orthopedic medical technology company focused on pain relief and musculoskeletal treatment through hyaluronic acid viscosupplements, bone growth stimulators, and emerging surgical and regenerative medicine platforms. MDT: Global medical device leader deploying pacemakers, defibrillators, spinal implants, surgical robotics, and diabetes management systems to alleviate pain, restore health, and extend life across 150+ countries.
Side-by-side fundamentals
| Metric | BVS | MDT | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $11.63 | $81.89 | |
| Market cap as of 2026-07-23 | $972M | $105.1B | |
| P/E as of 2026-07-23 | 34.11 | 21.88 | MDT lower |
| PEG as of 2026-07-23 | 2.25 | 2.90 | BVS lower |
| Net margin as of 2026-07-23 | +4.9% | +13.2% | MDT higher |
| Gross margin as of 2026-07-23 | +68.7% | +65.3% | BVS higher |
| Operating margin as of 2026-07-23 | +9.9% | +17.8% | MDT higher |
| ROE as of 2026-07-23 | +16.3% | +9.8% | BVS higher |
| ROA as of 2026-07-23 | +4.2% | +5.2% | MDT higher |
| Debt / equity as of 2026-07-23 | 1.49 | 0.57 | MDT lower |
| Revenue growth (YoY) as of 2026-07-23 | +1.5% | +8.4% | MDT higher |
| Revenue CAGR (3y) SEC XBRL | +3.5% | +5.2% | MDT higher |
| Dividend yield as of 2026-07-23 | n/a | +3.5% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-07-23 | 0.70 | 0.57 | |
| 1-year return as of 2026-07-22 close | +88.6% | -10.6% | BVS higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.